Drug
GP681 Simulant
GP681 Simulant is a pharmaceutical drug with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
2
67%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Recruiting2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 32 (66.7%)
Trials by Status
completed133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_3
Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza
NCT06574503
recruitingphase_3
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
NCT06573008
completedphase_2
A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza
NCT04736758
Clinical Trials (3)
Showing 3 of 3 trials
NCT06574503Phase 3
Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza
NCT06573008Phase 3
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
NCT04736758Phase 2
A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3